"This study provides the first evidence of a formulation-and dose-dependent ION risk, with the strongest association observed for Wegovy," the researchers concluded
Human Studies In humans, evidence is more limited, but some early findings are promising: Small pilot studies suggest that patients taking semaglutide show subtle changes in gut microbial composition after several months of treatment
Un estudio publicado en 2021 en la revista acadmica New England Journal of Medicine mostr una prdida media de peso del 14,9% en pacientes obesos que utilizaron semaglutida una vez a la semana, y cambiaron los hbitos de vida, durante 68 semanas (15 meses)
Patients with statin intolerance should first consider evidence-based alternatives like ezetimibe, bempedoic acid, PCSK9 inhibitors, or inclisiran before considering GLP-1 therapy primarily for lipid management
Most of these cases were mild and settled as treatment continued